IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy

Bispecific T cell engagers (TCEs) show promising clinical efficacy in blood tumors, but their application to solid tumors remains challenging. Here, we show that Fc-fused IL-7 (rhIL-7-hyFc) changes the intratumoral CD8 T cell landscape, enhancing the efficacy of TCE immunotherapy. rhIL-7-hyFc induces a dramatic increase in CD8 tumor-infiltrating lymphocytes (TILs) in various solid tumors, but the majority of these cells are PD-1-negative tumor non-responsive bystander T cells. However, they are non-exhausted and central memory-phenotype CD8 T cells with high T cell receptor (TCR)-recall capacity that can be triggered by tumor antigen-specific TCEs to acquire tumoricidal activity. Single-cell transcriptome analysis reveals that rhIL-7-hyFc-induced bystander CD8 TILs transform into cycling transitional T cells by TCE redirection with decreased memory markers and increased cytotoxic molecules. Notably, TCE treatment has no major effect on tumor-reactive CD8 TILs. Our results suggest that rhIL-7-hyFc treatment promotes the antitumor efficacy of TCE immunotherapy by increasing TCE-sensitive bystander CD8 TILs in solid tumors.

Fc-fused IL-7 provides broad antiviral effects against respiratory virus infections through IL-17A-producing pulmonary innate-like T cells

Repeated pandemics caused by the influenza virus and severe acute respiratory syndrome coronavirus (SARS-CoV) have resulted in serious problems in global public health, emphasizing the need for broad-spectrum antiviral therapeutics against respiratory virus infections. Here, we show the protective effects of long-acting recombinant human interleukin-7 fused with hybrid Fc (rhIL-7-hyFc) against major respiratory viruses, including influenza virus, SARS-CoV-2, and respiratory syncytial virus. Administration of rhIL-7-hyFc in a therapeutic or prophylactic regimen induces substantial antiviral effects. During an influenza A virus (IAV) infection, rhIL-7-hyFc treatment increases pulmonary T cells composed of blood-derived interferon γ (IFNγ)+ conventional T cells and locally expanded IL-17A+ innate-like T cells. Single-cell RNA transcriptomics reveals that rhIL-7-hyFc upregulates antiviral genes in pulmonary T cells and induces clonal expansion of type 17 innate-like T cells. rhIL-7-hyFc-mediated disease prevention is dependent on IL-17A in both IAV- and SARS-CoV-2-infected mice. Collectively, we suggest that rhIL-7-hyFc can be used as a broadly active therapeutic for future respiratory virus pandemic.

Understanding the Host Innate Immune Responses against SARS-CoV-2 Infection and COVID-19 Pathogenesis

The emergence of a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has become a significant health concern worldwide. Undoubtedly, a better understanding of the innate and adaptive immune responses against SARS-CoV-2 and its relationship with the coronavirus disease 2019 (COVID-19) pathogenesis will be the sole basis for developing and applying therapeutics. This review will summarize the published results that relate to innate immune responses against infections with human coronaviruses including SARS-CoV-1 and SARS-CoV-2 in both humans and animal models. The topics encompass the innate immune sensing of the virus to the dysregulation of various innate immune cells during infection and disease progression.

B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8+ tumor-infiltrating lymphocytes

Cancer immunotherapy with 4-1BB agonists has limited further clinical development because of dose-limiting toxicity. Here, we developed a bispecific antibody (bsAb; B7-H3×4-1BB), targeting human B7-H3 (hB7-H3) and mouse or human 4-1BB, to restrict the 4-1BB stimulation in tumors. B7-H3×m4-1BB elicited a 4-1BB-dependent antitumor response in hB7-H3-overexpressing tumor models without systemic toxicity. BsAb primarily targets CD8 T cells in the tumor and increases their proliferation and cytokine production. Among the CD8 T cell population in the tumor, 4-1BB is solely expressed on PD-1⁺Tim-3⁺ "terminally differentiated" subset, and bsAb potentiates these cells for eliminating the tumor. Furthermore, the combination of bsAb and PD-1 blockade synergistically inhibits tumor growth accompanied by further increasing terminally differentiated CD8 T cells. B7-H3×h4-1BB also shows antitumor activity in h4-1BB-expressing mice. Our data suggest that B7-H3×4-1BB is an effective and safe therapeutic agent against B7-H3-positive cancers as monotherapy and combination therapy with PD-1 blockade.

Hybrid Fc-fused interleukin-7 induces an inflamed tumor microenvironment and improves the efficacy of cancer immunotherapy

Objectives

Emerging oncotherapeutic strategies require the induction of an immunostimulatory tumor microenvironment (TME) containing numerous tumor‐reactive CD8⁺ T cells. Interleukin‐7 (IL‐7), a T‐cell homeostatic cytokine, induces an antitumor response; however, the detailed mechanisms underlying the contributions of the IL‐7 to TME remain unclear. Here, we aimed to investigate the mechanism underlying the induction of antitumor response by hybrid Fc‐fused long‐acting recombinant human IL‐7 (rhIL‐7‐hyFc) through regulation of both adaptive and innate immune cells in the TME.

Methods

We evaluated rhIL‐7‐hyFc‐mediated antitumor responses in murine syngeneic tumor models. We analysed the cellular and molecular features of tumor‐infiltrating lymphocytes (TILs) and changes in the TME after rhIL‐7‐hyFc treatment. Furthermore, we evaluated the antitumor efficacy of rhIL‐7‐hyFc combined with chemotherapy and checkpoint inhibitors (CPIs).

Results

Systemic delivery of rhIL‐7‐hyFc induced significant therapeutic benefits by expanding CD8⁺ T cells with enhanced tumor tropism. In tumors, rhIL‐7‐hyFc increased both tumor‐reactive and bystander CD8⁺ TILs, all of which displayed enhanced effector functions but less exhausted phenotypes. Moreover, rhIL‐7‐hyFc suppressed the generation of immunosuppressive myeloid cells in the bone marrow of tumor‐bearing mice, resulting in the immunostimulatory TME. Combination therapy with chemotherapy and CPIs, rhIL‐7‐hyFc elicited a strong antitumor response and even under a T lymphopenic condition by restoring CD8⁺ T cells. When combined with chemotherapy and CPIs, rhIL‐7‐hyFc administration enhanced antitumor response under intact andlymphopenic conditions by restoring CD8⁺ T cells.

Conclusion

Taken together, these data demonstrate that rhIL‐7‐hyFc induces antitumor responses by generating T‐cell‐inflamed TME and provide a preclinical proof of concept of immunotherapy with rhIL‐7‐hyFc to enhance therapeutic responses in the clinic.

Abstract 6673: B7-H3-targeted 4-1BB activation potentiates CD8 T cell-dependent antitumor immunity without systemic toxicity

4-1BB is a costimulatory receptor on activated T and NK cells, and the stimulation of 4-1BB by the natural ligand or agonistic mAb enhances cellular proliferation and effector functions. Immunotherapy targeting 4-1BB has been tested for cancer patients; however, dose-limiting toxicities of 4-1BB agonists restrict further clinical development. B7-H3 (CD276) is overexpressed on the cell surface of multiple cancers and tumor-associated endothelial cells, yet barely on healthy adult tissues. To restrict 4-1BB stimulation activity in tumors, we have developed an FcγR-binding null bispecific IgG1 antibody consisting of B7-H3-targeting IgG and two anti-4-1BB single-chain variable fragments. The B7-H3x4-1BB bispecific antibody (B5x1D8) shows a potent in vitro T cell costimulatory activity in the presence of B7-H3 on the tumor cells. B5x1D8 rapidly accumulates in B7-H3-overexpressing tumors compared to 4-1BB agonistic mAb. B5x1D8 elicits a 4-1BB-dependent anti-tumor response in three different B7-H3-overexpressing murine tumor models. More importantly, in contrast to 4-1BB mAb, B5x1D8 does not induce any observable systemic abnormalities. Treatment of B5x1D8 increases the density, cytokine production, and proliferation of CD8 T cells in the tumor. Characterization of TILs indicates that B5x1D8 increases the number of PD-1+TIM-3+ “terminal effector” CD8 T cells for eliminating tumor cells. Furthermore, a combination of B5x1D8 and immune checkpoint blockade (ICB), anti-PD1, synergistically inhibits tumor growth. The human 4-1BB-targeting bispecific antibody also induces B7-H3-dependent 4-1BB costimulation and inhibits tumor growth in human 4-1BB transgenic mice. In sum, our data suggest that the B7-H3x4-1BB bispecific antibody represents an alternative form of IgG-based 4-1BB agonistic mAb for effective and safe cancer immunotherapy against B7-H3 positive cancers as monotherapy and combination therapy with other immunotherapy, like ICB.

Citation Format: Gihoon You, Yangsoon Lee, Yeon-Woo Kang, Han Wook Park, Kyeongsu Park, Jaeho Jung, Seung-Woo Lee. B7-H3-targeted 4-1BB activation potentiates CD8 T cell-dependent antitumor immunity without systemic toxicity [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 6673.

Producing persistent, high-current, high-duty-factor H- beams for routine 1 MW operation of Spallation Neutron Source (invited)

Since 2009, the Spallation Neutron Source (SNS) has been producing neutrons with ion beam powers near 1 MW, which requires the extraction of ∼50 mA H(-) ions from the ion source with a ∼5% duty factor. The 50 mA are achieved after an initial dose of ∼3 mg of Cs and heating the Cs collar to ∼170 °C. The 50 mA normally persist for the entire 4-week source service cycles. Fundamental processes are reviewed to elucidate the persistence of the SNS H(-) beams without a steady feed of Cs and why the Cs collar temperature may have to be kept near 170 °C.

rf improvements for Spallation Neutron Source H- ion source

The Spallation Neutron Source at Oak Ridge National Laboratory is ramping up the accelerated proton beam power to 1.4 MW and just reached 1 MW. The rf-driven multicusp ion source that originates from the Lawrence Berkeley National Laboratory has been delivering approximately 38 mA H(-) beam in the linac at 60 Hz, 0.9 ms. To improve availability, a rf-driven external antenna multicusp ion source with a water-cooled ceramic aluminum nitride (AlN) plasma chamber is developed. Computer modeling and simulations have been made to analyze and optimize the rf performance of the new ion source. Operational statistics and test runs with up to 56 mA medium energy beam transport beam current identify the 2 MHz rf system as a limiting factor in the system availability and beam production. Plasma ignition system is under development by using a separate 13 MHz system. To improve the availability of the rf power system with easier maintenance, we tested a 70 kV isolation transformer for the 80 kW, 6% duty cycle 2 MHz amplifier to power the ion source from a grounded solid-state amplifier.

Computer simulations for rf design of a Spallation Neutron Source external antenna H- ion source

Electromagnetic modeling of the multicusp external antenna H(-) ion source for the Spallation Neutron Source (SNS) has been performed in order to optimize high-power performance. During development of the SNS external antenna ion source, antenna failures due to high voltage and multicusp magnet holder rf heating concerns under stressful operating conditions led to rf characteristics analysis. In rf simulations, the plasma was modeled as an equivalent lossy metal by defining conductivity as sigma. Insulation designs along with material selections such as ferrite and Teflon could be included in the computer simulations to compare antenna gap potentials, surface power dissipations, and input impedance at the operating frequencies, 2 and 13.56 MHz. Further modeling and design improvements are outlined in the conclusion.

Deciduoid peritoneal mesothelioma: CT findings with pathologic correlation

We report a rare case of deciduoid peritoneal mesothelioma in a 47-year-old woman who had no history of asbestos exposure or previous surgery. Immunohistochemistry and electron microscopic findings showed that the tumor was a subtype of epithelioid mesothelioma. Awareness of this disease entity is helpful for the differential diagnosis of peritoneal masses.

Nonspecific motor disorder of the esophagus: a real disorder or a manometric curiosity?

BACKGROUND

Nonspecific esophageal motility disorder (NEMD) has become a catchall term to describe abnormal esophageal manometric findings that do not meet strict criteria for established esophageal motility disorders. The aim of this study was to determine whether NEMD is a real esophageal motility disorder characterized by impairment of its motor function or simply a manometric disturbance with no clinical consequences.

METHODS

Esophageal transit of liquid and semisolids was studied using radioscintigraphic techniques in 10 symptomatic patients with manometrically diagnosed NEMD, 26 healthy control subjects, and 40 disease control subjects. The disease controls included 24 patients with achalasia, 9 with scleroderma, and 7 with diffuse esophageal spasm.

RESULTS

Patients with NEMD had no impairment of liquid emptying compared with healthy controls. Liquid emptying was markedly delayed in patients with achalasia and scleroderma. However, semisolid emptying was markedly delayed in patients with NEMD compared with healthy controls (P < 0.001), and the extent of its delayed emptying was similar to that seen in patients with achalasia, scleroderma, and diffuse esophageal spasm.

CONCLUSIONS

NEMD is not a manometric curiosity but a disorder characterized by selective impairment of semisolid emptying.

Reduction of RF penetration effects in high field imaging

A method of correcting for the RF inhomogeneity in the body by dielectric loading of the coil-to-shield space in an RF resonator (coil and shield assembly) is described. The presence of the RF coil and RF shield have significant effects on RF homogeneity. Based on theoretical calculations, a method for adjusting the RF homogeneity by manipulating the axial propagation constant, kappa z, is proposed. This is accomplished by loading the coil-to-shield space with dielectric material of suitable relative permittivity so as to increase kappa z and decrease the radial propagation constant, kappa rho. In this manner, the radial wavelength (lambda rho = 2 pi/kappa rho) can be increased relative to the body dimensions, and the field amplitude variations in the axial plane minimized. Theoretical calculations indicate that a value of between 30 and 40 for the relative permittivity of the dielectric material in the coil-to-shield space would reduce the RF field inhomogeneity from +/- 15% to about +/- 3% over a central 30-cm-diameter region of a homogeneous 40-cm-diameter body at both 64 and 170 MHz. The theoretical model was verified in laboratory measurements of the [formula; see text] field generated in a test coil at 170 MHz which was scaled to correspond to a body at 64 MHz. However, the improved RF field homogeneity would be accompanied by increased RF power requirements and reduced coil sensitivity.

Gastroparesis: diagnostic and therapeutic strategies

Impairment of gastrointestinal motility is common among patients with chronic dyspepsia. Gastroparesis can lead to devastating clinical consequences including malnutrition, weight loss, metabolic acidosis and psychological dysfunction. In this article, the current concepts of gastric motor function are reviewed and the diagnostic and treatment modalities of gastroparesis are discussed in detail.

An analytical model for the design of RF resonators for MR body imaging

A closed form, analytical solution describing the RF fields generated by an RF body coil resonator for MR imaging at 1.5 and 4.0 T is presented. This solution extends the results of earlier studies of RF penetration in the body by explicitly including the RF coil, the RF shield, and the field variation along the z axis for high-pass bird cage coils. A salient feature of this treatment is the calculation of the axial propagation constant, kz, which determines the z dependence of the RF field. We have determined the relative power deposition in the body, the B1 field homogeneity, and coil losses, which are functions of the coil-to-shield separation and body size. The relative power deposition in the body has been calculated to vary as the 1.58 power of the body radius. The calculations have also predicted that the field homogeneity in the z direction exhibits greater degradation at higher frequencies in a high-pass coil than in a low-pass coil. The model predicts an increase in coil losses by a factor of 2.8 as the coil-to-shield separation is reduced from 5 to 2 cm in a standard body resonator. Although the results for only a homogeneous cylindrical object or body are presented, the theory can be extended to a multilayered heterogeneous object of varying permittivity and conductivity.

Structure and transcription of the mitochondrial genome in heteroplasmic strains of Saccharomyces cerevisiae

Saccharomyces cerevisiae strain FF1210-6C/170 is respiratory deficient due to a mutation of the penultimate base of the mitochondrial tRNA(Asp) gene. We have identified a number of progeny from this strain which have reverted to respiratory sufficiency by the excision and tandem amplification of a small region of the mitochondrial (mt) DNA carrying the tRNA(Asp) gene, while also maintaining the full-length mtDNA. We have studied the structure of the mtDNA and mitochondrial transcription in a number of these heteroplasmic strains. The exact site of the recombination involved in the excision of the repeating unit of the amplified mtDNA has been determined for five of the revertants. Recombination occurs between identical sequences 4-13 base pairs in length. Each of the different repeating units of the amplified DNA retains an active promoter which has been moved to a site just upstream of the tRNA(Asp) gene by the excision/amplification. Transcripts from the heteroplasmic strains have been characterized to determine the sites of mitochondrial RNA termini. We find that in addition to the 5' and 3' processing of the tRNAs, many of the transcripts terminate at a position about 300 base pairs downstream of the gene for tRNA(Asp). We also find that 3' processing of tRNA(Asp) precursors is absent in petite strains which lack 5' processing indicating that 5' processing of tRNA(Asp) may be a prerequisite for 3' processing in this mutant.

Nuclear and mitochondrial revertants of a yeast mitochondrial tRNA mutant

We isolated revertants capable of respiration from the respiratory deficient yeast mutant, FF1210-6C/170, which displays greatly decreased mitochondrial protein synthesis due to a single base substitution at the penultimate base of the tRNAAsp gene on mitochondrial (mt) DNA. Three classical types of revertant were identified: (1) same-site revertants; (2) intragenic revertants which restore the base pairing in the acceptor stem of the mitochondrial tRNAAsp; and (3) extragenic suppressors located in nuclear DNA. In addition a fourth type of revertant was identified in which the mutant tRNAAsp is amplified due to the maintenance of both the original mutant mtDNA and a modified form of the mutant mtDNA in which only a small region around the tRNAAsp gene is retained and amplified. The latter form resembles the mtDNA in vegetative petite (rho-) strains which normally segregates rapidly from the wild-type mtDNA. Each revertant type was characterized genetically and by both DNA sequence analysis of the mitochondrial tRNAAsp gene and analysis of the quantity and size of RNA containing the tRNAAsp sequence. These results indicate that the mitochondrial tRNAAsp of the mutant retains a low level of activity and that the presence of the terminal base pair in tRNAAsp is a determinant of both tRNAAsp function and the maintenance of wild-type levels of tRNAAsp.

A case with some components of Cronkhite-Canada syndrome in a family with Peutz-Jeghers syndrome

A case with some components of Cronkhite-Canada syndrome such as onycholdystrophy, a large amount of diarrhea, hypoproteinemia and hypoalbuminemia in a 16 year-old man with Peutz-Jeghers syndrome was studied. His family members were conirmed to have Peutz-Jeghers syndrome by biopsy of polyps in the rectum and duodenum. This is the first case report of Peutz-Jeghers syndrome associated with some components of Cronkhite-Canada syndrome.